Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study
This post hoc subgroup analysis of the ALMS trial (comparing MMF to cyclophosphamide in lupus nephritis) specifically assessed patients with GFR < 30 ml/min/1.73m2. No difference was detected in the primary outcome of response to treatment (decrease in proteinuria and stabilization or improvement of serum creatinine level). The accompanying editorial asks whether post-hoc subgroup analyses should change treatment patterns: https://readbyqxmd.com/read/23582251/mycophenolate-mofetil-in-severe-lupus-nephritis-should-post-hoc-analyses-change-treatment-patterns
- Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
- Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
- Remote ischaemic preconditioning (RIPC) leads to sustained improvement in allograft function following live donor (LD) kidney transplantation: 5 year follow up in the REnal Protection Against Ischaemia Reperfusion in transplantation (REPAIR) study